Lisata Therapeutics Inc banner

Lisata Therapeutics Inc
NASDAQ:LSTA

Watchlist Manager
Lisata Therapeutics Inc Logo
Lisata Therapeutics Inc
NASDAQ:LSTA
Watchlist
Price: 4.55 USD -0.22%
Market Cap: $40.1m

Lisata Therapeutics Inc
Research & Development

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Lisata Therapeutics Inc
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
Lisata Therapeutics Inc
NASDAQ:LSTA
Research & Development
-$9.8m
CAGR 3-Years
40%
CAGR 5-Years
-1%
CAGR 10-Years
11%
Abbvie Inc
NYSE:ABBV
Research & Development
-$8.8B
CAGR 3-Years
-10%
CAGR 5-Years
-8%
CAGR 10-Years
-8%
Gilead Sciences Inc
NASDAQ:GILD
Research & Development
-$5.7B
CAGR 3-Years
-5%
CAGR 5-Years
-2%
CAGR 10-Years
-7%
Amgen Inc
NASDAQ:AMGN
Research & Development
-$7.2B
CAGR 3-Years
-17%
CAGR 5-Years
-11%
CAGR 10-Years
-6%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Research & Development
-$3.9B
CAGR 3-Years
-16%
CAGR 5-Years
-16%
CAGR 10-Years
-15%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Research & Development
-$5.2B
CAGR 3-Years
-13%
CAGR 5-Years
-14%
CAGR 10-Years
-12%
No Stocks Found

Lisata Therapeutics Inc
Glance View

Market Cap
40.1m USD
Industry
Biotechnology

Lisata Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Basking Ridge, New Jersey and currently employs 27 full-time employees. Lisata Therapeutics, Inc., formerly Caladrius Biosciences, Inc., is a clinical-stage biopharmaceutical company. The firm is engaged in the discovery, development, and commercialization of therapies for the treatment of advanced solid tumors and other major diseases. The firm focuses primarily on advancing its CendR Platform technology product candidates in a range of oncology indications. Its lead investigational product candidate, LSTA1, is designed to modify the tumor microenvironment by activating an uptake pathway that allows anti-cancer drugs to penetrate solid tumors. LSTA1 actuates an active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are not affected. In addition, the Company also has clinical development programs based on its autologous CD34+ cell therapy technology platform.

LSTA Intrinsic Value
2.24 USD
Overvaluation 51%
Intrinsic Value
Price

See Also

What is Lisata Therapeutics Inc's Research & Development?
Research & Development
-9.8m USD

Based on the financial report for Sep 30, 2025, Lisata Therapeutics Inc's Research & Development amounts to -9.8m USD.

What is Lisata Therapeutics Inc's Research & Development growth rate?
Research & Development CAGR 10Y
11%

Over the last year, the Research & Development growth was 14%. The average annual Research & Development growth rates for Lisata Therapeutics Inc have been 40% over the past three years , -1% over the past five years , and 11% over the past ten years .

Back to Top